Although it has been shown that adding Straumann^® Emdogain^® to a coronally advanced flap (CAF) procedure leads to clinical results after one and after ten years comparable to a CAF procedure with an autologous connective tissue graft¹ , the addition of a connective tissue graft is still recommended when treating patients with a thin gingival biotype² . Tissue harvesting is associated with patient discomfort and a higher risk for post-operative complications. The combined application of Straumann^® Emdogain^® and botiss mucoderm^® is a valid alternative to autologous tissue grafts³.

Straumann^® Emdogain^® is a unique gel containing enamel matrix derivative of porcine origin. The main component is amelogenin, which has demonstrated the ability to stimulate certain cells types involved in the healing process of soft and hard tissues towards a regenerative pattern, thus leading to true periodontal regeneration and accelerated oral wound healing. In root coverage procedures, using Straumann^® Emdogain^® leads to:

• Improved root coverage when compared with coronally advanced flap (CAF) procedures alone^4-7
• Improved quantity of keratinized tissue⁵
• True regeneration as shown in human histological studies⁸
• Less post-operative pain and swelling for the patient⁹   

botiss mucoderm^® provides a true alternative to the patient’s connective tissue graft in certain indications (recession coverage Miller class I-III ^10-12, broadening of attached gingiva¹³, soft tissue augmentation/thickening^14-17). This stable 3-dimensional collagen soft tissue replacement, made of porcine dermis, supports fast revascularization and soft tissue integration, including color and texture. As an alternative to autologous tissue grafts, using botiss mucoderm^® leads to:

• The maintenance or an increase in soft tissue thickness
• Good integration into the surrounding tissue with respect to color and texture
• Reduced patient chair time
• No donor site morbidity
• No pain associated with tissue harvesting